Panos M Fidias

Summary

Affiliation: Massachusetts General Hospital
Country: USA

Publications

  1. doi request reprint Phase III study of immediate compared with delayed docetaxel after front-line therapy with gemcitabine plus carboplatin in advanced non-small-cell lung cancer
    Panos M Fidias
    Massachusetts General Hospital, Center for Thoracic Cancers, 55 Fruit St, Boston, MA 02114, USA
    J Clin Oncol 27:591-8. 2009
  2. ncbi request reprint Long-term results of combined modality therapy in primary bone lymphomas
    P Fidias
    Department of Medical Oncology, Massachusetts General Hospital and Harvard Medical School, Boston, USA
    Int J Radiat Oncol Biol Phys 45:1213-8. 1999
  3. ncbi request reprint A phase II study of weekly paclitaxel in elderly patients with advanced non-small cell lung cancer
    P Fidias
    Division of Hematology Oncology, Massachusetts General Hospital, 100 Blossom Street, Cox 201, Boston, MA 02114, USA
    Clin Cancer Res 7:3942-9. 2001
  4. doi request reprint Phase I study of the c-raf-1 antisense oligonucleotide ISIS 5132 in combination with carboplatin and paclitaxel in patients with previously untreated, advanced non-small cell lung cancer
    Panos Fidias
    Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts 02114, USA
    J Thorac Oncol 4:1156-62. 2009
  5. doi request reprint Strategies for prolonged therapy in patients with advanced non-small-cell lung cancer
    Panos Fidias
    Center for Thoracic Cancers, Massachusetts General Hospital, Boston, MA 02114, USA
    J Clin Oncol 28:5116-23. 2010
  6. doi request reprint Phase 1-2a multicenter dose-ranging study of canfosfamide in combination with carboplatin and paclitaxel as first-line therapy for patients with advanced non-small cell lung cancer
    Lecia V Sequist
    Massachusetts General Hospital Cancer Center, Boston, Massachusetts 02114, USA
    J Thorac Oncol 4:1389-96. 2009
  7. pmc Potential of 18F-FDG PET toward personalized radiotherapy or chemoradiotherapy in lung cancer
    Noah C Choi
    Department of Radiation Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
    Eur J Nucl Med Mol Imaging 40:832-41. 2013

Detail Information

Publications7

  1. doi request reprint Phase III study of immediate compared with delayed docetaxel after front-line therapy with gemcitabine plus carboplatin in advanced non-small-cell lung cancer
    Panos M Fidias
    Massachusetts General Hospital, Center for Thoracic Cancers, 55 Fruit St, Boston, MA 02114, USA
    J Clin Oncol 27:591-8. 2009
    ..This phase III, randomized trial assessed the efficacy and safety of docetaxel administered either immediately after GC or at disease progression...
  2. ncbi request reprint Long-term results of combined modality therapy in primary bone lymphomas
    P Fidias
    Department of Medical Oncology, Massachusetts General Hospital and Harvard Medical School, Boston, USA
    Int J Radiat Oncol Biol Phys 45:1213-8. 1999
    ..To report the Massachusetts General Hospital experience in the management of patients with primary bone lymphoma (PBL) treated with combined modality therapy (CMT)...
  3. ncbi request reprint A phase II study of weekly paclitaxel in elderly patients with advanced non-small cell lung cancer
    P Fidias
    Division of Hematology Oncology, Massachusetts General Hospital, 100 Blossom Street, Cox 201, Boston, MA 02114, USA
    Clin Cancer Res 7:3942-9. 2001
    ..Our aim was to evaluate the efficacy, toxicity, and pharmacokinetic behavior of single-agent paclitaxel given weekly to elderly patients with lung cancer...
  4. doi request reprint Phase I study of the c-raf-1 antisense oligonucleotide ISIS 5132 in combination with carboplatin and paclitaxel in patients with previously untreated, advanced non-small cell lung cancer
    Panos Fidias
    Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts 02114, USA
    J Thorac Oncol 4:1156-62. 2009
    ....
  5. doi request reprint Strategies for prolonged therapy in patients with advanced non-small-cell lung cancer
    Panos Fidias
    Center for Thoracic Cancers, Massachusetts General Hospital, Boston, MA 02114, USA
    J Clin Oncol 28:5116-23. 2010
    ..Although current guidelines recommend a maximum of six cycles of first-line therapy, even in responding patients, recent trials have shown benefit with maintenance therapy...
  6. doi request reprint Phase 1-2a multicenter dose-ranging study of canfosfamide in combination with carboplatin and paclitaxel as first-line therapy for patients with advanced non-small cell lung cancer
    Lecia V Sequist
    Massachusetts General Hospital Cancer Center, Boston, Massachusetts 02114, USA
    J Thorac Oncol 4:1389-96. 2009
    ..We aimed to evaluate the safety and efficacy of canfosfamide in combination with carboplatin and paclitaxel as first-line therapy in patients with locally advanced or metastatic non-small cell lung cancer...
  7. pmc Potential of 18F-FDG PET toward personalized radiotherapy or chemoradiotherapy in lung cancer
    Noah C Choi
    Department of Radiation Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
    Eur J Nucl Med Mol Imaging 40:832-41. 2013
    ..We investigated the metabolic response of lung cancer to radiotherapy or chemoradiotherapy by (18)F-FDG PET and its utility in guiding timely supplementary therapy...